米非司酮在子宫内膜异位症患者中的综合应用效果观察  

Observation of the comprehensive application effect of Mifepristone in the patients with endometriosis

作　　者：袁迎九[1] 后建丽[1] 丁文清[1] 

机构地区：[1]深圳市龙岗区妇幼保健院,广东深圳518172

出　　处：《中国当代医药》2016年第34期92-94,共3页China Modern Medicine

摘　　要：目的 观察及研究米非司酮在子宫内膜异位症患者中的综合应用效果。方法 选取2013年4月~2015年7月于我院进行诊疗的80例子宫内膜异位症患者为研究对象,根据随机分配的原则将其分为对照组和观察组,每组各40例。对照组采用孕三烯酮进行治疗,观察组则以米非司酮进行治疗。治疗前后采用WHOQOL-BREF评分对患者进行生存质量评估;观察比较不同r-AFS分期患者的治疗总有效率、治疗前后不同时间（治疗后3、6个月）的内分泌指标水平（FSH、E2、LH）。结果 观察组中r-AFS分期Ⅰ~Ⅱ期及Ⅲ~Ⅳ期患者的治疗总有效率分别为94.44%、86.36%,均高于对照组的72.22%及68.18%（χ2=5.267,6.123,均P〈0.05）;且治疗后不同时间的FSH、E2、LH水平均高于对照组患者（P〈0.05）;WHOQOL-BREF评分也均高于对照组患者（P〈0.05）。结论 米非司酮在子宫内膜异位症患者中的综合应用效果较好,对于患者的内分泌不良影响较小,对于患者生存质量的改善作用也更为明显。Objective To observe and study the comprehensive application effect of Mifepristone in the patients with endometriosis.Methods Eighty patients with endometriosis in our hospital from April 2013 to July 2015 were selected as the research object,and patients were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with gestrinone,the observation group was treated with Mifepristone.Before and after treatment the WHOQOL-BREF score was used to evaluate the survival quality of patients;the total effective rate and level of endocrine （FSH,E2,LH） of patients with different r-AFS staging at different time before and after treatment （3,6 months ofter treatment） was compared.Results The total effective rate of patients with r-AFS stages Ⅰ to Ⅱ and stages Ⅲ to Ⅳ in the observation group was 94.44% and 86.36% respectively, was higher than 72.22% and 68.18% of the control group （X^2=5.267,6.123,all P〈0.05）;the levels of FSH,E2,LH at different time after the treatment were higher than those of the control group （P〈0.05）;the WHOQOL-BREF scores were all higher than those of control group （P〈0.05）.Conelusion Comprehensive application of Mifepristone has better effect in patients with endometriosis, and less influence on the endocrine of patients,the improvement role for the life quality of patients is more obvious.

关 键 词：米非司酮 孕三烯酮 子宫内膜异位症 综合应用 效果 

分 类 号：R711.71[医药卫生—妇产科学]